BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 37652546)

  • 1. Prediction of Response to
    Hohberg M; Reifegerst M; Drzezga A; Wild M; Schmidt M
    J Nucl Med; 2023 Nov; 64(11):1758-1764. PubMed ID: 37652546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiation Dosimetry for
    Okamoto S; Thieme A; Allmann J; D'Alessandria C; Maurer T; Retz M; Tauber R; Heck MM; Wester HJ; Tamaki N; Fendler WP; Herrmann K; Pfob CH; Scheidhauer K; Schwaiger M; Ziegler S; Eiber M
    J Nucl Med; 2017 Mar; 58(3):445-450. PubMed ID: 27660138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Examining Absorbed Doses of Indigenously Developed
    Kamaldeep ; Wanage G; Sahu SK; Maletha P; Adnan A; Suman S; Basu S; Das T; Banerjee S
    Cancer Biother Radiopharm; 2021 Apr; 36(3):292-304. PubMed ID: 32379495
    [No Abstract]   [Full Text] [Related]  

  • 4. Pretherapeutic Comparative Dosimetry of
    Feuerecker B; Chantadisai M; Allmann A; Tauber R; Allmann J; Steinhelfer L; Rauscher I; Wurzer A; Wester HJ; Weber WA; d'Alessandria C; Eiber M
    J Nucl Med; 2022 Jun; 63(6):833-839. PubMed ID: 34531260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The
    Maffey-Steffan J; Scarpa L; Svirydenka A; Nilica B; Mair C; Buxbaum S; Bektic J; von Guggenberg E; Uprimny C; Horninger W; Virgolini I
    Eur J Nucl Med Mol Imaging; 2020 Mar; 47(3):695-712. PubMed ID: 31776632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Intrapatient Dosimetry Comparison of
    Rinscheid A; Gäble A; Wienand G; Pfob C; Dierks A; Kircher M; Trepel M; Weckermann D; Lapa C; Bundschuh RA
    J Nucl Med; 2023 Dec; 64(12):1918-1924. PubMed ID: 37770108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dosimetry of
    Violet J; Jackson P; Ferdinandus J; Sandhu S; Akhurst T; Iravani A; Kong G; Kumar AR; Thang SP; Eu P; Scalzo M; Murphy D; Williams S; Hicks RJ; Hofman MS
    J Nucl Med; 2019 Apr; 60(4):517-523. PubMed ID: 30291192
    [No Abstract]   [Full Text] [Related]  

  • 8. Lesion Dosimetry for [
    Grkovski M; O'Donoghue JA; Imber BS; Andl G; Tu C; Lafontaine D; Schwartz J; Thor M; Zelefsky MJ; Humm JL; Bodei L
    J Nucl Med; 2023 Nov; 64(11):1779-1787. PubMed ID: 37652541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate-Specific Membrane Antigen Radioligand Therapy Using
    Schuchardt C; Zhang J; Kulkarni HR; Chen X; Müller D; Baum RP
    J Nucl Med; 2022 Aug; 63(8):1199-1207. PubMed ID: 34887335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 1 trial to determine the maximum tolerated dose and patient-specific dosimetry of [
    Zang J; Wang G; Zhao T; Liu H; Lin X; Yang Y; Shao Z; Wang C; Chen H; Chen Y; Zhu Z; Miao W; Chen X; Zhang J
    Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):871-882. PubMed ID: 37864592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic efficacy, prognostic variables and clinical outcome of
    Suman S; Parghane RV; Joshi A; Prabhash K; Bakshi G; Talole S; Banerjee S; Basu S
    Br J Radiol; 2019 Dec; 92(1104):20190380. PubMed ID: 31600089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The
    Scarpa L; Buxbaum S; Kendler D; Fink K; Bektic J; Gruber L; Decristoforo C; Uprimny C; Lukas P; Horninger W; Virgolini I
    Eur J Nucl Med Mol Imaging; 2017 May; 44(5):788-800. PubMed ID: 28083690
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Karimzadeh A; Heck M; Tauber R; Knorr K; Haller B; D'Alessandria C; Weber WA; Eiber M; Rauscher I
    J Nucl Med; 2023 Mar; 64(3):402-409. PubMed ID: 36137758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pretherapeutic 68Ga-PSMA-617 PET May Indicate the Dosimetry of 177Lu-PSMA-617 and 177Lu-EB-PSMA-617 in Main Organs and Tumor Lesions.
    Wang J; Zang J; Wang H; Liu Q; Li F; Lin Y; Huo L; Jacobson O; Niu G; Fan X; Zhu Z; Chen X
    Clin Nucl Med; 2019 Jun; 44(6):431-438. PubMed ID: 30985422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of machine learning to pretherapeutically estimate dosimetry in men with advanced prostate cancer treated with
    Xue S; Gafita A; Dong C; Zhao Y; Tetteh G; Menze BH; Ziegler S; Weber W; Afshar-Oromieh A; Rominger A; Eiber M; Shi K
    Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4064-4072. PubMed ID: 35771265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-in-human dosimetry of gastrin-releasing peptide receptor antagonist [
    Kurth J; Krause BJ; Schwarzenböck SM; Bergner C; Hakenberg OW; Heuschkel M
    Eur J Nucl Med Mol Imaging; 2020 Jan; 47(1):123-135. PubMed ID: 31482426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Experience with [
    Alan-Selcuk N; Beydagi G; Demirci E; Ocak M; Celik S; Oven BB; Toklu T; Karaaslan I; Akcay K; Sonmez O; Kabasakal L
    J Nucl Med; 2023 Oct; 64(10):1574-1580. PubMed ID: 37620050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual-Time-Point Posttherapy
    Straub M; Kupferschläger J; Serna Higuita LM; Weissinger M; Dittmann H; la Fougère C; Fiz F
    J Nucl Med; 2023 Sep; 64(9):1431-1438. PubMed ID: 37414446
    [No Abstract]   [Full Text] [Related]  

  • 19. Evaluation of
    Pathmanandavel S; Crumbaker M; Ho B; Yam AO; Wilson P; Niman R; Ayers M; Sharma S; Hickey A; Eu P; Stockler M; Martin AJ; Joshua AM; Nguyen A; Emmett L
    J Nucl Med; 2023 Feb; 64(2):221-226. PubMed ID: 36008120
    [No Abstract]   [Full Text] [Related]  

  • 20. First-in-human study of
    Zang J; Fan X; Wang H; Liu Q; Wang J; Li H; Li F; Jacobson O; Niu G; Zhu Z; Chen X
    Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):148-158. PubMed ID: 30090965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.